LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Accueil・Liste d'Actions・MacroGenics Inc

MacroGenics Inc

Fermé

SecteurSoins de santé

4.21 1.94

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.03

Max

4.34

Chiffres clés
By Trading Economics
Revenu	-31M -14M
Ventes	-32M 41M
BPA	-0.22
Marge bénéficiaire	-34.333
Employés	293
EBITDA	-37M -15M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+83.48% upside

Dividendes
By Dow Jones
Prochains Résultats	19 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	65M 188M
Ouverture précédente	2.27
Clôture précédente	4.21

Sentiment de l'Actualité

By Acuity

35%

65%

112 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Neutral Evidence

1.47 / 1.64 Support & Résistance

MacroGenics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mai 2026, 22:27 UTC

Acquisitions, Fusions, Rachats

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mai 2026, 22:12 UTC

Résultats

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mai 2026, 21:52 UTC

Acquisitions, Fusions, Rachats

LVMH to Sell Marc Jacobs

15 mai 2026, 00:00 UTC

Résultats

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mai 2026, 23:57 UTC

Acquisitions, Fusions, Rachats

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 mai 2026, 23:56 UTC

Acquisitions, Fusions, Rachats

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mai 2026, 23:47 UTC

Résultats

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mai 2026, 23:47 UTC

Résultats

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mai 2026, 23:46 UTC

Résultats

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mai 2026, 23:46 UTC

Résultats

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mai 2026, 22:11 UTC

Acquisitions, Fusions, Rachats

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mai 2026, 22:04 UTC

Résultats

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mai 2026, 22:00 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mai 2026, 21:55 UTC

Résultats

Nu Holdings 1Q EPS 18c >NU

14 mai 2026, 21:55 UTC

Résultats

Nu Holdings 1Q Rev $4.97B >NU

Comparaison

Variation de prix

MacroGenics Inc prévision

Objectif de Prix

By TipRanks

83.48% hausse

Prévisions sur 12 Mois

Moyen 6.33 USD 83.48%

Haut 9 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.47 / 1.64Support & Résistance

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

112 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.